Apr 17, 2023 7:00am EDT Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application
Apr 04, 2023 7:00am EDT Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study
Apr 03, 2023 7:00am EDT Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M
Mar 02, 2023 8:00am EST Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board
Feb 21, 2023 7:00am EST Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor
Feb 16, 2023 7:00am EST Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase
Jan 17, 2023 7:00am EST Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study
Jan 11, 2023 7:00am EST Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board
